AEterna Zentaris (AEZS) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a buy rating to a hold rating in a report released on Monday.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Separately, ValuEngine lowered shares of AEterna Zentaris from a sell rating to a strong sell rating in a research note on Monday, September 17th. One equities research analyst has rated the stock with a sell rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $3.25.

NASDAQ:AEZS traded up $0.07 during mid-day trading on Monday, reaching $2.20. The company’s stock had a trading volume of 700 shares, compared to its average volume of 1,157,606. AEterna Zentaris has a 1 year low of $1.12 and a 1 year high of $3.25. The firm has a market cap of $38.96 million, a PE ratio of -1.63 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. AEterna Zentaris had a net margin of 34.40% and a return on equity of 87.85%. The company had revenue of $0.66 million during the quarter. As a group, sell-side analysts predict that AEterna Zentaris will post 0.05 EPS for the current fiscal year.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Featured Article: How to Invest in an Index Fund

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply